华润医药(03320.HK)独家代理吉利德五个产品
华润医药(03320.HK)旗下全资子公司华润医药商业宣布,独家代理吉利德科学公司五个产品,将持续深化与吉利德的战略合作。华润医药为吉利德在中国的全面战略合作夥伴。截至目前,华润医药商业共独家进口代理了吉利德的五个产品,包括舒发泰(抗爱滋病药物)、韦立得(新一代乙肝抗病毒药)、维帕他韦(丙肝新药,吉二代)、丙通沙(丙肝新药,吉三代)及必妥维(历史上最强效的HIV整合(酉每)抑制剂)。
另外,近日吉利德及其在研药物Remdesivir(瑞德西韦)作为治疗新型冠状病毒的可能有效治疗药物备受关注。目前,吉利德正与中国卫生当局密切合作。2月6日,瑞德西韦正式被用於武汉新型冠状病毒肺炎患者治疗。吉利德自2016年进入中国进行商业运营,共有八款创新药在中国上市,覆盖丙肝、乙肝和爱滋病等抗病毒领域,其中五个产品则由华润医药独家进口代理。华润医药商业早於2018年11月与吉利德签署了双方全面战略合作协定,华润医药商业承接抗爱滋病药物Truvada(舒发泰)的全国销售业务,以及未来吉利德在中国上市的抗病毒性传染病药物的进口总代理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.